Abstract
Introduction
Migraine, in particular migraine with aura, has been found to be associated with cardiovascular disease. However, the role of conventional vascular risk factors in the association is still debated. The aim of the present review is to address the association between migraine and conventional cardiovascular risk factors as well as to address their possible role in the association between migraine and cardiovascular disease.
Methods
Data for this review were obtained through searches in multiple sources up to May 2014 using the terms “migraine” OR “headache” in combination with all the vascular risk factors of interest.
Results
Data about the possible association between migraine and high blood pressure values are heterogeneous, hindering any final conclusion. Data addressing the possible association between migraine and diabetes mellitus indicate the lack of any association or in some cases a negative association between the two conditions. The body of evidence on the role of dyslipidemia in migraineurs is relatively homogeneous and, with few exceptions, reports an association between migraine and an unfavorable lipid profile; however, the difference in lipid levels between migraineurs and non-migraineurs is small and its clinical implication unclear. Regarding obesity, a trend has been observed of increased risk of migraine with increasing obesity, especially in young patients, albeit in the midst of conflicting data. Evidence about the association between cigarette smoking and migraine mostly indicates that migraineurs are more commonly smokers than non-migraineurs. On the other hand, the majority of the available studies report less alcohol use in migraineurs than in non-migraineurs. Finally, many of the available studies suggest a more frequent family history of cardiovascular disease in migraineurs as compared to non-migraineurs. Since most of the studies that supported the association between migraine and cardiovascular disease adjusted the analyses for the presence of several vascular risk factors, they cannot entirely explain this association.
Conclusions
Based on the available reported data, it seems unlikely that the higher risk of cardiovascular disease in migraineurs is mediated by any single vascular risk factor. For this reason the role of specific interactions among risk factors with the contribution of genetic, environmental, personality and psychological factors should be appropriately investigated.
Keywords
Introduction
Migraine, in particular migraine with aura (MA), has been found to be associated with cardiovascular disease (CVD) (1–19). Mechanisms underlying the hypothesized causal relationship between migraine and CVD have not yet been established. It is improbable that CVD occurs exclusively through the conventional mechanisms commonly recognized in the general population (e.g. atherosclerosis and small vessel disease); migraine-specific mechanisms are probably involved. Additionally, whether ischemic stroke and ischemic heart disease share common mechanisms in migraineurs is still unproven. Several studies have addressed the burden of conventional vascular risk factors (RFs) in migraineurs. However, in some areas results from the available studies are conflicting and definitive conclusions cannot be drawn. In this review we will examine the association between migraine and conventional vascular RFs such as arterial hypertension, diabetes mellitus (DM), dyslipidemia, obesity, cigarette smoking, alcohol consumption, and family history of CVD; additionally we will briefly address their possible role in the association between migraine and CVD.
Methods
Data for this review were obtained through searches in Embase, Google Scholar, ISI Web of Science, and Medline from their first availability up to May 2014. The search terms included “migraine” OR “headache” AND (“arterial hypertension,” “diabetes mellitus,” “dyslipidemia,” “hypercholesterolemia,” “obesity,” “body mass index,” “cigarette smoking,” “alcohol,” “history of cardiovascular disease”). We also searched reference lists and papers cited in the identified articles. We considered only studies addressing, as their primary or secondary aim, the difference in the distribution of vascular RFs between migraineurs and non-migraineurs. We excluded studies using as the reference group participants with non-migraine headache, not defining migraine or the RF of interest, performed on individuals with metabolic disease only, or not adopting a matching procedure or adjusted analyses to account for possible confounders. When studies provided more than one adjusted model, we used the one including the largest number of factors. Where a cohort study analyzed the association between migraine and the RF of interest considering only baseline data, we have reported the study as cross-sectional in our results. We reviewed only studies published in English.
Results
Blood pressure (BP)
Summary of selected studies addressing the relationship between migraine and blood pressure.
BP=blood pressure, CI=confidence interval, DBP= diastolic blood pressure, MA=migraine with aura, MO=migraine without aura, NR=not reported, OR=odds ratio, SBP=systolic blood pressure.
Cohort studies reporting the association in a cross sectional analysis.
The Genetic Epidemiology of Migraine (GEM), a large, well-conducted cross-sectional study, reported that individuals with migraine had a 1.64 increase in the risk of presenting a history of physician-diagnosed hypertension (25). This finding was consistent both in patients with MA and with migraine without aura (MO). In line with this observation, the National Health and Nutrition Examination Survey (NHANES), a prospective cohort study involving 12,220 participants, reported an increased risk of migraine in individuals with arterial hypertension; no details were provided regarding MA or MO (24). The prospective cohort Bruneck study also indicated, in an analysis of cross-sectional data, that hypertension was more common in migraineurs than in controls (26). Additionally, two cross-sectional studies in Taiwan using administrative coding data supported this same observation (6,30). In line with those findings, a case-control study on Japanese patients, showed higher values for both systolic BP (SBP) and diastolic BP (DBP) in migraineurs as compared to non-migraineurs, regardless of migraine subtype (23).
On the other hand, some studies did not find a clear association between the presence of hypertension and migraine, or indeed indicated the presence of an inverse relationship (Table 1). Several reports from the Nord-Trøndelag Health (HUNT) Study, a prospective cohort study involving a large number of participants from adolescence to adulthood, indicated in cross-sectional analyses that individuals with hypertension or high BP values were not at increased risk of migraine (22,27,28). Similarly, a cross-sectional population-based study, the Saõ Paulo Ageing & Health (SPAH) Study, did not find an increased risk of hypertension in migraineurs but suggested the presence of an inverse association in women (20). This last finding is in line with those reported by the large cross-sectional Reykjavik Study (21), by cross-sectional data from the prospective Epidemiology of Vascular Aging (EVA) Study (29), and by some reports from a cross-sectional Brazilian study (31) and from the HUNT-2 study (32) suggesting a decreased risk of migraine associated with high BP values (31) or lower mean BP values in migraineurs (32).
Diabetes Mellitus (DM)
Summary of selected studies addressing the relationship between migraine and diabetes mellitus.
BMI= body mass index, BP= blood pressure, CI=confidence interval, DM=diabetes mellitus, DM1=diabetes mellitus type 1, DM2=diabetes mellitus type 2, HR=hazard ratio, MA=migraine with aura, MO=migraine without aura, NR=not reported, OR=odds ratio, SBP= systolic blood pressure.
Cohort studies reporting the association in a cross sectional analysis.
Data from the NHANES (24) and the SPAH study (20) indicated that migraineurs were not at increased risk of DM nor were diabetics at increased risk of migraine. Similarly, the analysis of data from the Women’s Health Study (WHS) cohort of women without DM at baseline showed that patients with a past history of migraine, active MA or active MO were not at increased risk of developing type 2 DM as compared to non-migrainous women (33). In addition, a similar prevalence of DM in migraineurs and non-migraineurs has been reported by the cross-sectional Bruneck study (26) and by the two retrospective cross-sectional studies in Taiwan using administrative coding data (6,30). The case-control study on Japanese subjects showed no differences in indicators of DM (fasting blood sugar and hemoglobin A1C) between migraineurs and non-migraineurs (23).
At variance with this, some data indicate a negative association between migraine and DM. A cross-sectional analysis of data from the prospective cohort HUNT study found that both patients with type 1 and type 2 DM were less likely to report a previous history of migraine than patients without DM (34). A lower frequency of migraine in patients with DM as compared to patients without DM was also reported by an early case-control study (36). Similar conclusions were drawn by a Norwegian cross-sectional study based on the analysis of data related to drug prescription (35). The study found that patients with DM had an overall reduced prevalence of medically treated migraine as compared to the non-diabetic population, and that the trend was progressively more pronounced with advancing age.
Dyslipidemia
Summary of selected studies addressing the relationship between migraine and dyslipidemia.
BMI= body mass index, CI=confidence interval, CM= chronic migraine; HDL-C=high density lipoprotein cholesterol, ICD-9-CM=International Classification of Diseases 9th revision Clinical Modification, TC=total cholesterol, LDL-C=low density lipoprotein cholesterol, MA=migraine with aura, MO=migraine without aura, NR=not reported, OR=odds ratio, RR=relative risk.
Cohort studies reporting the association in a cross sectional analysis.
The cross-sectional GEM study demonstrated that patients with MA were more likely to have high total cholesterol and high total/high-density lipoprotein (HDL) cholesterol ratio as compared to other groups while there was no association between high total cholesterol and MO (25). However, in this study, the difference in mean blood values of total cholesterol between patients with MA and the other groups was modest and the clinical relevance of this small difference needs to be clarified. Cross-sectional data from the WHS cohort supported these findings indicating an increased risk of having higher level of total cholesterol and non-HDL cholesterol in participants with migraine than in non-migraineurs; in this study the analysis performed according to migraine type was inconclusive (38). Data from the cross-sectional EVA study also indicated an association between migraine and dyslipidemia; individuals with high total cholesterol and high triglyceride levels had an increased risk of MA but not of MO (39). Further evidence for an association between migraine and dyslipidemia came from a case-control study on 205 patients; migraineurs as compared to non-migraineurs had an increased risk of hypertriglyceridemia, hypercholesterolemia, low HDL cholesterol, and high low-density lipoprotein (LDL) cholesterol (41). Three studies on Taiwanese individuals, all with a retrospective design and using administrative coding data, recognized a higher prevalence of dyslipidemia in migraineurs as compared to non-migraineurs (6,30) or an increased risk of hyperlipidemia in patients with chronic migraine than non-migraineurs (37), while the previously mentioned case-control study of Japanese participants found that migraineurs had increased values of total cholesterol and LDL cholesterol and decreased values of HDL cholesterol, without any difference between migraine subtypes (23).
Some data have pointed to a negative association between migraine and dyslipidemia or to the lack of any association. In the HUNT study, lower levels of both total and HDL cholesterol values were reported, especially in MA (32). The multivariate analysis showed an inverse association between high total cholesterol values and MO but not MA, along with a positive association between high HDL cholesterol levels and MA or MO. A negative association between migraine and dyslipidemia was reported also by a case-control study with a small sample size (40). This study reported results stratified for obesity status, making comparison with other studies difficult. The Bruneck study reported no differences in mean values of blood lipids between migraineurs and non-migraineurs (26).
Obesity
Summary of selected studies addressing the relationship between migraine and obesity.
BMI=body mass index (expressed in Kg/m2), CDH= chronic daily headache, CI=confidence interval, CM=chronic migraine, HR=hazard ratio, MA=migraine with aura, MO=migraine without aura, NR=not reported, OR=odds ratio, TM=transformed migraine.
Cohort studies reporting the association in a cross sectional analysis.
At variance several other studies did not support an association between migraine and obesity. Data from a cross-sectional analysis of the NHANES cohort showed the absence of an increased risk of migraine in obese participants (24). Similarly, a large cross-sectional study pooling data from different data sets showed an increased risk of headache in general among obese women, but not specifically of migraine (48). In line with these findings, two large cross-sectional population-based studies conducted in the United States (US) did not find an increased risk of migraine associated with obesity (42,53); this same finding was supported by the German DMKG Headache Study (60). In agreement with those results, a cross-sectional study did not find an increased risk of active migraine or inactive migraine in obese women (49). A further cross-sectional study indicated that obesity was not associated with an increased risk of headache including migraine (50). In the cross-sectional GEM study, there was no difference between mean BMI values in migraineurs and non-migraineurs (25). Additionally, the cross-sectional Bruneck study (26), the case-control Japanese study (23), and a further case-control study on Mexican participants (56) reported similar BMI values or obesity prevalence in migraineurs when compared to non-migraineurs. Data from the cross-sectional, population-based German Headache Consortium Study showed that obese individuals did not have an increased risk of chronic migraine as compared to non-obese participants (55).
Cigarette smoking
Most of the available data point to an association between cigarette smoking and migraine (24,25,32,50,54,63–68) although there are some discordant findings (20,26,69).
In the cross-sectional Collaborative Perinatal Project (involving 508 migrainous pregnant women and 3192 non-migrainous pregnant women), migraineurs were reported to smoke more heavily and to have a longer smoking history as compared to non-migraineurs (64). Similarly, a higher prevalence of smokers among migraineurs was reported by the cross-sectional population-based Erasmus Rucphen Family (ERF) study, in particular for MA (49% vs 31% in controls; p < 0.001) (63) and by the HUNT Study (32). Data from the prospective cohort NHANES reported a positive association between lifetime smoking history and migraine (odds ratio (OR) for migraine 1.2, 95% confidence interval (CI) 1.0–1.3; p < 0.001) while no association was reported between current smoking and migraine (OR for migraine 1.1, 95% CI 0.9–1.4) (24). Interesting data also came from the cross-sectional GEM study, showing a greater likelihood of migraine in smokers (25). In detail, there was an association between any migraine and being a former smoker (OR 1.25, 95% CI 1.0–1.6; p < 0.05), smoking fewer than 20 cigarettes per day (OR 1.35; 95% CI 1.0–1.8; p < 0.05), smoking more than 20 cigarettes per day (OR 1.59, 95% CI 1.2–2.2; p < 0.05) and between MA and smoking more than 20 cigarettes per day (OR 2.14, 95% CI 1.3–3.5; p < 0.05) while MO was not associated with any smoking status. A positive association between migraine and smoking was also reported by the prospective cohort Coronary Artery Risk Development in Young Adults (CARDIA) study, showing an increased risk of developing migraine along a follow-up period in current smokers at baseline (adjusted relative hazard 1.35, 95% CI 1.08–1.68) (65). The prospective cohort HUNT study identified an increased risk of migraine in younger (<40 years) smokers as compared to “never smokers” (OR 1.2, 95% CI 1.1–1.4 in those smoking <10 cigarettes/day and OR 1.3, 95% CI 1.2–1.5 in those smoking ≥10 cigarettes day) (66). Interestingly, a positive association was confined to younger smokers whereas a negative association was found in elderly smokers (OR 0.8, 95% CI 0.7–0.9 in those smoking <10 cigarettes/day and OR 0.8, 95% CI 0.7–0.9 in those smoking ≥10 cigarettes day). Further support for a positive association was provided by a cross-sectional Swedish population-based study (adjusted OR for headache in current smokers 1.3, 95% CI 1.2–1.4) (50), and by a cross-sectional study on German students, reporting an association between daily smoking and migraine (adjusted OR 2.7, 95% CI 1.3–5.6) (67). Lastly, similar conclusions have also been drawn from the youth part of the HUNT study, which found an association between smoking and migraine (adjusted OR for migraine in smokers 1.8, 95% CI 1.4–2.2) (54) and from a hospital-based case-control study conducted in Dhaka, Bangladesh, that found a six-fold increased risk of migraine in tobacco smokers as compared to non-smokers (adjusted OR 6.6, 95% CI 2.2–19.6) (68).
The prospective cohort Bruneck study found no difference in the prevalence of cigarette smoking, in an analysis of cross-sectional data, according to migraine status and subtype (26). Additionally, data from the SPAH (20) and from the large cross-sectional Spanish National Health Survey (SNHS) (69) confirmed the lack of any association and rejected the hypothesis of an association between migraine and smoking.
Alcohol consumption
Most of the available data indicate the occurrence of lower alcohol consumption in migraineurs as compared to non-migraineurs or the lack of any association between the two conditions. The cross-sectional GEM study found that migraineurs overall as well as migraineurs with MA and MO were less likely to consume alcohol than non-migraineurs (25). A cross-sectional study on medical students reported that individuals with migraine had lower alcohol consumption than participants without any headache (70). The absence of any association has been suggested by the Bruneck study (26), the SPAH study (20), and the ERF study (63), this latter showing similar alcohol consumption between migraineurs, irrespective of migraine subtype, and controls. In line with these results, the NHANES showed no increased risk of migraine in alcohol users (>12 drinks per year) than non-users (OR 1.1, 95% CI 0.9–1.2) (24). Moreover, an inverse relationship between alcohol consumption and headache including migraine, with a decreased risk of migraine in alcohol users, has been highlighted by a Swedish population-based study (adjusted OR 0.7, 95% CI 0.7–0.8 for headache in heavy alcohol users at least once a month) (50) and by the large cross-sectional SNHS (crude OR 0.54, 95% CI 0.49–0.59) (69). Further evidence came from the HUNT Study (32), which highlighted the presence of a higher proportion of alcohol abstainers among migraineurs, both with MA and MO, as compared to non-migraineurs. Finally, contrasting results have been reported by a cross-sectional study on German students that found an association between wine consumption and migraine (adjusted OR for migraine in consumers of one or more glasses/week 2.2, 95% CI 1.1–4.3) (67).
Family history of CVD
Many of the available studies indicate that a family history of CVD is frequently associated with migraine. A parental history of early myocardial infarction (<60 years of age) was more frequently found in migraineurs in the cross-sectional GEM study (25). Further evidence came from cross-sectional analysis of data from the large cohort HUNT Study, showing a higher likelihood of having a first-degree relative with early myocardial infarction in patients with MA and a higher likelihood of having a first-degree relative with stroke in patients with both MA and MO (28). With respect to migraine subtypes, no differences between patients with MA and MO were found by the Japanese case-control study. This study found an association between family history of CVD and migraine, irrespective of migraine subtype (23).
Global role of RFs in the association between migraine and CVD
Vascular RFs might contribute to increasing the risk of vascular events in migraineurs through an atherosclerosis-mediated pathway. However, there is no agreement in considering migraineurs as more prone to developing atherosclerosis as compared to non-migraineurs (71–74). Although little information is available on the frequency of ischemic stroke subtypes in migraineurs, the available data suggest that most strokes in migraineurs are not of atherothrombotic etiology (72,75). In the same way, the majority of cardiac events in migraineurs seem not to be attributable to atherothrombosis (71,73). In addition, migraine has not been reliably associated with an increase in intima-media thickness (29,63,76,77), which is a marker of forthcoming atherosclerosis and an independent predictor of future risk for ischemic cardiac and cerebral events (78). In addition, conventional vascular RFs do not play a confounding role in the association between migraine and CVD, as suggested by studies that support the association between the two conditions even after the adjustment of results for conventional vascular RFs (online Supplementary Table) (1–15).
Some studies have suggested that stroke risk is increased most in migraineurs with a favorable cardiovascular RF profile (5,75). Non-hypertensives, nonsmokers and nondiabetics are the individuals with the greatest increase in the risk of ischemic stroke associated with migraine (5,75) while there is an increased risk of ischemic stroke in migraineurs in the presence of cigarette smoking (79,80). Moreover, data from the WHS (49) indicated that the association between MA and vascular events differed according to vascular risk status: in fact, the association between MA and ischemic stroke was proven only among women in the lowest Framingham risk score group, while the association with myocardial infarction was proven only among women in the highest score group. With regard to the individual components of the Framingham risk score, this pattern of association was driven by a particularly increased risk of ischemic stroke among women with MA who were young (aged 45–49 years) and who had low total cholesterol levels. In contrast, women with MA who had high total cholesterol levels had an increased risk of myocardial infarction.
Discussion
Summary of findings
We found various studies that have addressed the burden of conventional vascular RFs in migraineurs. However, in some areas results from the available studies are conflicting and definitive conclusions cannot be drawn. Several factors may account for the extreme variability of the above results, including the use of different sampling criteria (selected versus unselected populations), the study design, the selection of criteria and procedures to diagnose migraine and to detect RF of interest (questionnaires, personal visits, medical records) with changing definitions over time, and inadequate control for confounders other than age and gender in some of the studies. The available data about the possible association between migraine and high BP values are particularly heterogeneous. Data addressing the possible association between migraine and DM indicate the lack of any association or in some cases a negative association between the two conditions. The body of evidence referring to the presence of dyslipidemia in migraineurs is relatively homogeneous and, with few exceptions, reports an association between migraine and an unfavorable lipid profile. However, the clinical relevance of the association remains questionable, as the difference in lipid levels between migraineurs and non-migraineurs was small despite statistical significance. Regarding obesity, a trend of increased risk of migraine with increasing obesity was observed, especially in young participants. However, no conclusive statement can be made because there are numerous conflicting data. Obesity may also represent an RF for migraine chronification. Evidence for an association between cigarette smoking and migraine is less controversial, and most of the available data support the existence of a positive relationship. On the other hand, most of the available studies did not find an association between migraine and increased alcohol consumption, and some have indicated reduced alcohol use in migraineurs compared with non-migraineurs. If moderate alcohol consumption is cardioprotective, migraineurs may be disadvantaged in this regard. Finally, many of the available studies suggested a more frequent family history of CVD in migraineurs as compared to non-migraineurs.
If vascular RFs played an active role, a greater frequency of atherothrombosis would be expected in patients with migraine, whereas most of the studies did not lead to this conclusion. In line with this argument, the majority of the studies have demonstrated, through adjusted data analysis, the independence of the association between migraine and CVD from the presence of conventional vascular RFs. Indeed, the studies carried out to date do not provide enough data to establish any possible adjunctive role of vascular RFs in comorbidity with migraine.
Implications
It seems unlikely that the higher risk of CVD in migraineurs is mediated by conventional vascular RFs. Different and alternative mechanisms should be appropriately investigated. Currently, it is not possible to stratify the vascular risk of migraineurs on the basis of the concomitant presence of vascular RFs. The recognition of a comorbid vascular risk profile that exposes migrainous patients to a further increase in the risk of CVD is important for clinicians as it might help to identify individuals who may require a more strict control of the comorbid vascular RFs.
Strengths and limitations
A variety of studies have investigated the possible association between migraine and conventional vascular RFs. However, while for some factors (e.g. arterial hypertension, dyslipidemia, obesity) the studies are numerous, for others the data are more limited. Striking differences among the results of the available studies hinder definite conclusions and suggest that additional confounding elements may play a significant role. Differences in the research design of the studies may partly account for the heterogeneity of the results. Some of the data reported in this review were drawn by comparisons between group analyses adjusted for gender and age only and consequently the possible role of some major confounders cannot be excluded. In addition, there is a paucity of data addressing the question of any differences according to migraine subtype.
Potential clinical/public health implications
While the evidence that links migraine to CVD is robust, the overall increase in absolute risk of CVD in migraineurs is rather small. Unfortunately, at the moment there are no reliable features that may indicate which individuals, across the overall migraine population, are at the highest risk of vascular events. MA and conventional vascular RFs are independent predictors of CVD events. The multiplicative role that coexistent vascular RF may play in the overall risk for vascular events, in a context of mutual enhancement, is well recognized (81). However, in migraineurs the exact impact that comorbid vascular RFs may exert on overall CVD is still a matter of debate. It is imperative, however, in daily clinical practice, to pay attention to the presence of RFs, even in young migrainous patients, and to be sure that comorbidities such as arterial hypertension, DM and dyslipidemia are adequately treated by a vascular neurologist or by a primary care physician. All patients who have migraine should be advised not to smoke, while obese patients should be encouraged to lose weight using appropriate strategies. At the moment it is not clear if the vascular risk associated with migraine can be modified and there is currently no direct evidence to support the hypothesis that migraine treatment may reduce future stroke risk. No drugs are currently recommended for vascular event prevention in migraineurs. Patients with migraine should not be prescribed aspirin or other anti-thrombotics for cardiovascular prevention unless other (i.e. non-migraine) indications are clearly present. The same applies to migraineurs for whom magnetic resonance imaging of the brain shows white matter hyperintensities or infarct-like lesions. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers that in preliminary studies have shown some efficacy in migraine prevention (82) have also been associated with reduction of cardiovascular risk independently of their BP-lowering effect (83,84). However, further evidence is needed to support their role as a migraine-preventive treatment in the absence of high BP values and to demonstrate any possible benefit for the CVD risk of migraineurs. In addition, ergot alkaloids and triptans, two effective acute migraine treatments, may raise concerns regarding CVD safety because of their vasoconstrictive effect. However, the available data suggest that triptans when used at the suggested doses and in individuals without a history of CVD do not lead to increased CVD risk (4).
Recommendations for future studies
Future studies aimed at evaluating the burden of conventional vascular RFs in migraineurs should apply rigorous methodology with respect to the selection of cases, the diagnosis of migraine and the assessment of RFs of interest. The study sample should be adequately estimated in order to avoid the emergence of any biased association, and any possible confounding factors should be taken into account. Future studies should also clarify the role that comorbid RFs may play in the association between migraine and CVD to establish if comorbidities magnify the vascular risk of migraineurs.
Future research should also clarify the mechanisms that may explain the increased CVD risk in individuals with migraine. Studies have shown an association between migraine and stress (85) while stress is also a risk factor for CVD (86). Stress, personality traits and psychopathological status may be confounding factors in the association between migraine and CVD that, to date, are not accurately evaluated. Recent findings indicate that migraineurs have a vascular vulnerability in the brain but also at systemic levels, making them more susceptible to ischemic events in the presence of even mild triggers of ischemia (87). Biomarkers such as homocysteine, C-reactive protein, methylenetetrahydrofolate reductase, methionine synthase reductase, and von Willebrand factor should also be studied to understand their contribution to triggering ischemia or their role as markers of increased vascular risk in migraineurs (74,82,87). Studies should address the role of genetic factors. It is in fact possible that inherited factors may lead both to migraine and to vascular events. From this perspective, genome-wide-association studies may lead to some important conclusions. It would be useful to develop biomarkers or instrumental tests to enable the identification, among migraineurs, of any subgroup at particular increased risk of specific cardiovascular events. Studies should also establish if migraine is a modifiable or non-modifiable risk factor for CVD. Drugs acting on the renin-angiotensin system should be better studied, since there are data indicating that they may have a role in the prevention of migraine attacks and they may positively affect vascular risk.
Clinical implications
There is no solid evidence to demonstrate an increased burden of conventional vascular risk factors in migraineurs, with the only exceptions being dyslipidemia and cigarette smoking. The presence of conventional vascular risk factors cannot entirely explain the association between migraine and cardiovascular disease. Attempts to explain the possible mechanisms of an association between migraine and cardiovascular disease should not rely exclusively on the presence of comorbidities with vascular risk factors.
Footnotes
Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Conflict of interest
None declared.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
